AzurRx BioPharma Inc (AZRX)
Market Open
22 Sep, 04:00
NASDAQ (CM) NASDAQ (CM) Primary $
3. 45
+0.07
+2.07%
$
3.43M Market Cap
- P/E Ratio
0% Div Yield
629,030 Volume
- Eps
$ 3.38
Previous Close Day Range
3.38 3.66
Year Range
2.68 26.3
Want to track AZRX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
AZRX trading today higher at $3.45, an increase of 2.07% from yesterday's close, completing a monthly increase of or $3.45. Over the past 12 months, AZRX stock gained .
AZRX is not paying dividends to its shareholders.
The last earnings report, released on Oct 13, 2016, exceeded the consensus estimates by 0.72%. On average, the company has surpassed earnings expectations by 0.72%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).
AZRX Chart
AzurRx BioPharma Inc Dividends
AZRX is not paying dividends to its shareholders.
AzurRx BioPharma Inc Earnings
| 13 Oct 2016 Date | | - Cons. EPS | - EPS |
AZRX is not paying dividends to its shareholders.
| 13 Oct 2016 Date | | - Cons. EPS | - EPS |
AzurRx BioPharma Inc (AZRX) FAQ
What is the stock price today?
The current price is $3.45.
On which exchange is it traded?
AzurRx BioPharma Inc is listed on NASDAQ (CM).
What is its stock symbol?
The ticker symbol is AZRX.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0%.
What is its market cap?
As of today, the market cap is 3.43M.
Has AzurRx BioPharma Inc ever had a stock split?
No, there has never been a stock split.
AzurRx BioPharma Inc Profile
| Biotechnology Industry | Healthcare Sector | James Sapirstein CEO | NASDAQ (CM) Exchange | 05502L105 Cusip |
| US Country | 12 Employees | - Last Dividend | - Last Split | - IPO Date |
AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company is headquartered in Brooklyn, New York and currently employs 12 full-time employees. The firm is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The firm's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).
Contact Information
Address: 760 Parkside Ave Ste 304
Phone: 16466997855
Website: http://www.azurrx.com
2025 © Marketlog. All Rights Reserved.
